Literature DB >> 16297972

A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis.

Gautam G Rao1, Aleena Kurien, Diana Gossett, William F Griffith, Robert L Coleman, Carolyn Y Muller.   

Abstract

OBJECTIVES: Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene are thought to be associated with a varying risk of cervical dysplasia. The purpose of this trial was to study the role of the two common functional MHTFR polymorphisms in a large multiracial population at risk for cervical dysplasia and cancer.
METHODS: This is a nested case-control study of 376 subjects obtained from cohorts enrolled in an ongoing prospective cervical carcinogenesis protocol. Cases included invasive cancers (n = 51), and high (n = 50) and low (n = 50) grade dysplasia. There were 225 normal controls. Functional MTHFR 677C-->T and 1298A-->C genotypes were identified. Follow-up cytology data were reviewed for the control subjects from the time of study entry until August 2004.
RESULTS: There is a significant racial difference in allele frequency of the 677C-->T polymorphism (P < 0.005). African-American women had an extremely low prevalence of the 677T allele (8%). There was no significant difference in the frequency of the 677T allele between cases and controls. There is no racial difference in allele frequency of the 1298A-->C polymorphism. Also, no significant difference was found between cases and controls. Of the 51 cancers, no case was homozygous for both aberrant polymorphisms (677T, 1298C), and only 3 cases were heterozygous for both. Follow-up data were available for 129 of 225 control subjects (57%). Only 15 (12%) have had a subsequent abnormal pap, and there was no association with the 677C-->T polymorphism.
CONCLUSIONS: We confirm a significant difference in the 677T allele frequencies among racial groups. However, there is no association of either the 677C-->T or 1298A-->C polymorphisms in cervical carcinogenesis. There is no role of the combined polymorphism effect in cervical cancer or evidence of prediction for future Pap abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16297972     DOI: 10.1016/j.ygyno.2005.10.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals.

Authors:  Wen-Lei Zhuo; Liang Zhang; Jun-Jun Ling; Yi Zhu; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

2.  Association analyses suggest multiple interaction effects of the methylenetetrahydrofolate reductase polymorphisms on timing of menarche and natural menopause in white women.

Authors:  Pengyuan Liu; Yan Lu; Robert R Recker; Hong-Wen Deng; Volodymyr Dvornyk
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

Review 3.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

Review 4.  Review of studies on metabolic genes and cancer in populations of African descent.

Authors:  Camille C Ragin; Scott Langevin; Scott Rubin; Emanuela Taioli
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

5.  Effects of methylenetetrahydrofolate reductase single-nucleotide polymorphisms on breast, cervical, ovarian, and endometrial cancer susceptibilities.

Authors:  Zheng Wang; Kai Li; Ling Ouyang; Hidasa Iko; Ahmad Javid Safi; Shan Gao
Journal:  Chronic Dis Transl Med       Date:  2021-08-12

6.  A lower degree of PBMC L1 methylation in women with lower folate status may explain the MTHFR C677T polymorphism associated higher risk of CIN in the US post folic acid fortification era.

Authors:  Suguna Badiga; Gary L Johanning; Maurizio Macaluso; Andres Azuero; Michelle M Chambers; Nuzhat R Siddiqui; Chandrika J Piyathilake
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.